跳转到主要内容
  • 关于 ELGA
    • 关于 ELGA
    • 超纯水
    • 纯化技术
    • 水中杂质
    • 白皮书
    • 认证合作伙伴
    • 可持续发展
    • 降低临床风险
    • 招贤纳士
    • 活动
    • HPLC 的制药应用
    • HPLC 水纯度
  • 博客
    • Analytical Chemistry
    • Clinical & Pharma
    • Cool Science
    • Environment and sustainability
    • Life in the lab
    • Purelab product design
    • Science of the future
    • Water Purity
    • Water in the lab
  • 联系信息
  • English
  • Deutsch
  • Español
  • Français
  • Italiano
  • Português
  • 日本語
首页 ELGA LabWater
  • 产品
  • 应用
  • 案例分析
  • 支持
  • 产品
    • PURELAB
    • CENTRA
    • MEDICA
    • BIOPURE
    • ELGA 全产品系列
  • 应用
  • 案例分析
    • 借助超纯水,解开南极的秘密
    • 1+ 级超纯水对非专利药物开发的重要性
    • Ca’Foscari University- A New Method for Investigating Environmental Tracers in Ice
    • Ca’Foscari University- Investigating Contaminants in Antarctic Ice
    • DASA:巴西最大的医疗诊断公司
    • ELGA 帮助免疫血清学实验室最大程度地增加运行时间
    • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
    • PURELAB® flex:适合当今研究方法的理想培训系统
    • Sichere Reinstwasserversorgung für präzise Produkttests
    • Zentrale Reinstwasser-Aufbereitung für Analyser
    • 城市综合医院为西门子 ADVIA® 分析仪选配 MEDICA® Pro
    • 雅培诊断的南亚团队选用 ELGA MEDICA 系统
  • 支持
    • 支持和服务
    • 实验室规划
    • 注册产品
    • Register Your Product (USA & Canada Only)
  • 产品
    • PURELAB
      • PURELAB Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB Chorus 2+
      • PURELAB® Chorus 2
      • PURELAB® Chorus 3
      • PURELAB® flex 1 & 2
      • PURELAB® flex 3 & 4
    • CENTRA
      • CENTRA® 60/120
      • CENTRA® RDS
      • CENTRA® R200
    • MEDICA
      • MEDICA® 7/15
      • MEDICA® EDI 15/30
      • MEDICA® Pro EDI 60/120
      • MEDICA® Pro-LPS
      • MEDICA® Pro-R 和 Pro-RE
      • MEDICA® R200
    • BIOPURE
      • BIOPURE 7/15
      • BIOPURE 60/120
      • BIOPURE 200/300/600
    • ELGA 全产品系列
      • PURELAB® Classic
  • 应用
  • 案例分析
    • 借助超纯水,解开南极的秘密
    • 1+ 级超纯水对非专利药物开发的重要性
    • Ca’Foscari University- A New Method for Investigating Environmental Tracers in Ice
    • Ca’Foscari University- Investigating Contaminants in Antarctic Ice
    • DASA:巴西最大的医疗诊断公司
    • ELGA 帮助免疫血清学实验室最大程度地增加运行时间
    • Optimale Wasserqualität für mikrobiologische Forschung und Lehre
    • PURELAB® flex:适合当今研究方法的理想培训系统
    • Sichere Reinstwasserversorgung für präzise Produkttests
    • Zentrale Reinstwasser-Aufbereitung für Analyser
    • 城市综合医院为西门子 ADVIA® 分析仪选配 MEDICA® Pro
    • 雅培诊断的南亚团队选用 ELGA MEDICA 系统
  • 支持
    • 支持和服务
    • 实验室规划
    • 注册产品
    • Register Your Product (USA & Canada Only)
  • English
  • Deutsch
  • Español
  • Français
  • Italiano
  • Português
  • 日本語
  • 隐私政策
  • 条款和条件
  • 全球法律合规
  • 专利
  • 页面操作员
  • 首页
  • Node
  • A New Technique For Quantifying Bevacizumab In Eye Formulations
Clinical & Pharma
Science of the Future

A New Technique For Quantifying Bevacizumab In Eye Formulations

23 2月 2020
- by Dr Alison Halliday

Child eye test

Bevacizumab is a cancer drug that is also used ‘off-label’ to treat eye diseases. Researchers develop a rapid, sensitive and cost-effective new method for its routine analysis in ocular formulations.

Bevacizumab (Avastin®) is a monoclonal antibody that is approved for treating several types of cancer. By targeting the activity of vascular endothelial growth factor-A (VEGF-A) and blocking the growth of tumour blood vessels, this effectively cuts off the supply of oxygen and nutrients that fuel the tumour.

But ophthalmologists also use bevacizumab to treat chronic eye diseases caused by abnormal blood vessel growth in the retina at the back of the eye. These include the ‘wet’ type of age-related macular degeneration (AMD), which is a leading cause of blindness in older people. By injecting the antibody directly into the patient’s eyes, the aim is to block the growth of blood vessels and slow down sight loss. 

Although bevacizumab is not formally approved as an eye treatment, many consider it as an equally effective, yet cheaper alternative to a similar antibody called ranibizumab (Lucentis®) – which also targets VEGF-A and has been approved for this purpose.

Challenges Around Drug Delivery and Quality Control

A patient will need repeated doses of bevacizumab around every four to six weeks to maintain the drug at therapeutic levels in their eyes. But these injections are invasive and bring risks of potential complications. So scientists are aiming to develop sustained release systems – such as eye implants – that can enable longer-lasting delivery.

Another challenge is that biotherapeutic antibodies are not very stable – for example, they can aggregate, unfold or degrade, which can impact on their effectiveness. And so it is important that processes are in place that can facilitate the quality control of bevacizumab in eye formulations.

A Faster, Simpler and Cheaper Method

In a new study, researchers develop a new analytical method for use in in vitro studies of new eye implant delivery systems and in the routine quantification of bevacizumab in ophthalmic formulations.1 The scientists used size-exclusion chromatography (SEC) coupled with fluorescence detection. This is a powerful tool used for the preparation of biotherapeutics and represents a feasible alternative for other assays currently available for quantifying bevacizumab, which are both costly and time-consuming.

The researchers optimised their unique new chromatographic technique and then validated it for bevacizumab analysis, demonstrating that it is accurate, rapid and sensitive. The researchers made up the stock and standard solutions required for these experiments using an ELGA PURELAB® Flex laboratory water purification system.

This is the first study that couples SEC with fluorescence detector for the assay of bevacizumab. The results demonstrate that this method is cost-effective and suitable for the routine analysis of bevacizumab in pharmaceutical dosage forms –  and for measuring its levels in in vitro release studies of drug-loaded eye implants.

Why choose ELGA LabWater?

ELGA LabWater has been a trusted name in pure and ultrapure water since 1937. Our dedication to ultrapure and pure water is a guarantee that we will continue to provide the best solutions with the best service.

Reference:

  1. Jirgees, F. et al. A validated size exclusion chromatography method coupled with fluorescence detection for rapid quantification of bevacizumab in ophthalmic formulations. Journal of Pharmaceutical and Biomedical Analysis 2019; 174: 145-150.

Dr Alison Halliday
After completing an undergraduate degree in Biochemistry & Genetics at Sheffield University, Alison was awarded a PhD in Human Molecular Genetics at the University of Newcastle. She carried out five years as a Senior Postdoctoral Research Fellow at UCL, investigating the genes involved in childhood obesity syndrome. Moving into science communications, she spent ten years at Cancer Research UK engaging the public about the charity’s work. She now specialises in writing about research across the life sciences, medicine and health.

 

  • Enquiry
  • 获取报价
  • 预订演示
  • 联系获认证的合作伙伴

Enquiry

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

获取报价

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

预订演示

Please check this to confirm that you have read our Terms of Service and Privacy Policy.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

Elga LabWater 总部

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
电话: +44 (0) 203 567 7300
传真:+44 (0) 203 567 7205

超纯水专家

  • 支持和服务
  • 活动

案例研究

  • 雅培诊断
  • DASA 医学诊断
  • NeoDIN 医学研究所
  • 北斯塔福德郡 NHS 信托大学医院
  • Olsberg 职业技术学院

资源

  • 了解超纯水
  • 白皮书
  • 水纯化技术
  • 实验室应用
  • 水中杂质

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?
  • 语言
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Veolia 其他站点
    • Veolia
    • Veolia Fondation
    • Veolia Water Technologies

© VWS (UK) Ltd. 以 ELGA®LabWater 的名义经营业务。2021- 保留所有权利
ELGA 是 Veolia 旗下全球实验室用水品牌。

  • 隐私政策
  • 条款和条件
  • 全球法律合规
  • 专利
  • 页面操作员
Elga Veolia
TOP

© 2017 ELGA Veolia